应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02126 药明巨诺-B
休市中 08-23 16:08:27
1.330
-0.060
-4.32%
最高
1.390
最低
1.300
成交量
17.65万
今开
1.390
昨收
1.390
日振幅
6.47%
总市值
5.52亿
流通市值
5.52亿
总股本
4.15亿
成交额
23.33万
换手率
0.04%
流通股本
4.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
药明巨诺-B盘中异动 股价大跌6.47%报1.300港元
市场透视 · 08-23 15:25
药明巨诺-B盘中异动 股价大跌6.47%报1.300港元
药明巨诺-B(02126)股价下跌5.036%,现价港币$1.32
阿斯达克财经 · 08-23 15:25
药明巨诺-B(02126)股价下跌5.036%,现价港币$1.32
药明巨诺-B(02126)下跌6.25%,报1.35元/股
金融界 · 08-22 15:44
药明巨诺-B(02126)下跌6.25%,报1.35元/股
药明巨诺-B盘中异动 早盘大幅跳水5.49%报1.361港元
市场透视 · 08-22 10:26
药明巨诺-B盘中异动 早盘大幅跳水5.49%报1.361港元
药明巨诺-B08月20日主力资金流出15万元 连续3日减仓
自选股智能写手 · 08-20
药明巨诺-B08月20日主力资金流出15万元 连续3日减仓
药明巨诺-B(02126.HK)拟8月28日举行董事会会议批准中期业绩
格隆汇 · 08-14
药明巨诺-B(02126.HK)拟8月28日举行董事会会议批准中期业绩
药明巨诺-B盘中异动 早盘急速上涨5.40%报1.581港元
自选股智能写手 · 08-09
药明巨诺-B盘中异动 早盘急速上涨5.40%报1.581港元
药明巨诺-B盘中异动 早盘股价大涨6.03%
自选股智能写手 · 08-07
药明巨诺-B盘中异动 早盘股价大涨6.03%
药明巨诺-B(02126)股价上升5.298%,现价港币$1.59
阿斯达克财经 · 08-07
药明巨诺-B(02126)股价上升5.298%,现价港币$1.59
药明巨诺-B(02126)下跌8.93%,报1.53元/股
金融界 · 08-05
药明巨诺-B(02126)下跌8.93%,报1.53元/股
药明巨诺-B盘中异动 早盘股价大跌5.30%报1.591港元
自选股智能写手 · 08-05
药明巨诺-B盘中异动 早盘股价大跌5.30%报1.591港元
药明巨诺-B盘中异动 临近收盘大幅跳水7.34%报1.640港元
自选股智能写手 · 08-02
药明巨诺-B盘中异动 临近收盘大幅跳水7.34%报1.640港元
药明巨诺-B(02126)股价下跌5.65%,现价港币$1.67
阿斯达克财经 · 08-02
药明巨诺-B(02126)股价下跌5.65%,现价港币$1.67
信达前CCO刘敏履新药明巨诺CEO,能否卖好“天价疗法”?
界面 · 08-01
信达前CCO刘敏履新药明巨诺CEO,能否卖好“天价疗法”?
药明巨诺CEO李怡平离职,称目前无创业打算,前信达生物CCO刘敏接任
时代周报 · 07-31
药明巨诺CEO李怡平离职,称目前无创业打算,前信达生物CCO刘敏接任
药明巨诺换帅:刘敏接任首席执行官
21世纪经济报道 · 07-31
药明巨诺换帅:刘敏接任首席执行官
【药明巨诺-B(02126.HK):刘敏已获委任为行政总裁及执行董事】智通财经APP讯,药明巨诺-B(02126.HK)发布公告,刘敏已获委任为公司行政总裁及执行董事,自2024年7月31日起生效。
智通财经 · 07-31
【药明巨诺-B(02126.HK):刘敏已获委任为行政总裁及执行董事】智通财经APP讯,药明巨诺-B(02126.HK)发布公告,刘敏已获委任为公司行政总裁及执行董事,自2024年7月31日起生效。
药明巨诺-B(02126):刘敏已获委任为行政总裁及执行董事
智通财经 · 07-31
药明巨诺-B(02126):刘敏已获委任为行政总裁及执行董事
药明巨诺(02126.HK)委任首席执行官
阿斯达克财经 · 07-31
药明巨诺(02126.HK)委任首席执行官
药明巨诺-B盘中异动 大幅跳水5.00%
自选股智能写手 · 07-29
药明巨诺-B盘中异动 大幅跳水5.00%
公司概况
公司名称:
药明巨诺-B
所属市场:
SEHK
上市日期:
--
主营业务:
药明巨诺(开曼)有限公司是一家主要从事临床及临床前阶段细胞治疗的中国公司。该公司致力于为中国市场开发细胞治疗手段,为中国癌症患者带来新兴治疗方式。通过其子公司,其建立了一个专注为血液癌症及实体瘤开发、制造和商业化突破性细胞免疫疗法的一体化平台。其主打候选产品relmacabtagene autoleucel(relma-cel)是针对复发或难治(r/r)B细胞淋巴瘤的自体抗CD19 CAR-T疗法。该公司主要于中国市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02126","market":"HK","secType":"STK","nameCN":"药明巨诺-B","latestPrice":1.33,"timestamp":1724400507028,"preClose":1.39,"halted":0,"volume":176500,"delay":0,"floatShares":415077678,"shares":415077678,"eps":-2.045027,"marketStatus":"休市中","marketStatusCode":7,"change":-0.06,"latestTime":"08-23 16:08:27","open":1.39,"high":1.39,"low":1.3,"amount":233255,"amplitude":0.064748,"askPrice":1.33,"askSize":1000,"bidPrice":1.31,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-2.0450271129164297,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"listingDate":1604332800000,"adjPreClose":1.39,"openAndCloseTimeList":[[1724376600000,1724385600000],[1724389200000,1724400000000]],"volumeRatio":0.4901416274210217,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02126/wiki","defaultTab":"wiki","newsList":[{"id":"2461455857","title":"药明巨诺-B盘中异动 股价大跌6.47%报1.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461455857","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461455857?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:25","pubTimestamp":1724397903,"startTime":"0","endTime":"0","summary":"2024年08月23日下午盘15时25分,药明巨诺-B股票出现波动,股价急速跳水6.47%。截至发稿,该股报1.300港元/股,成交量15万股,换手率0.04%,振幅6.47%。资金方面,该股资金流入2.6925万港元,流出17.1105万港元。药明巨诺-B股票所在的生物技术行业中,整体跌幅为1.58%。其相关个股中,北海康成-B、宜明昂科-B、同源康医药-B涨幅较大,振幅较大的相关个股有北海康成-B、中国抗体-B、帝王国际投资,振幅分别为129.11%、19.85%、19.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315250398e35f70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315250398e35f70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02126","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2461582485","title":"药明巨诺-B(02126)股价下跌5.036%,现价港币$1.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2461582485","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461582485?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:25","pubTimestamp":1724397900,"startTime":"0","endTime":"0","summary":"[下跌股]药明巨诺-B(02126) 股价在下午03:25比前收市价下跌5.036%,现股价为港币$1.32。至目前为止,今日最高价为$1.39,而最低价为$1.32。总成交量为10.2万股,总成交金额为港币$13.55万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2408231143/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02126","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2461664753","title":"药明巨诺-B(02126)下跌6.25%,报1.35元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461664753","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461664753?lang=zh_cn&edition=full","pubTime":"2024-08-22 15:44","pubTimestamp":1724312665,"startTime":"0","endTime":"0","summary":"8月22日,药明巨诺-B(02126)盘中下跌6.25%,截至15:44,报1.35元/股,成交108.64万元。药明巨诺是一家专注于开发、生产和商业化细胞免疫治疗产品的创新型生物科技公司,目标是成为细胞免疫治疗领域的领导者。公司自2016年成立以来,已建立了涵盖血液肿瘤、实体肿瘤和自身免疫性疾病的细胞免疫治疗产品管线,并致力于用创新的、高品质的产品帮助全球患者得到治愈。截至2023年年报,药明巨诺-B营业总收入1.74亿元、净利润-7.68亿元。8月28日,药明巨诺-B将披露2024财年中报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/22154442601172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1161","02126","BK1583"],"gpt_icon":0},{"id":"2461933595","title":"药明巨诺-B盘中异动 早盘大幅跳水5.49%报1.361港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461933595","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461933595?lang=zh_cn&edition=full","pubTime":"2024-08-22 10:26","pubTimestamp":1724293608,"startTime":"0","endTime":"0","summary":"2024年08月22日早盘10时26分,药明巨诺-B股票出现异动,股价快速跳水5.49%。截至发稿,该股报1.361港元/股,成交量7.55万股,换手率0.02%,振幅4.17%。资金方面,该股资金流入2.7835万港元,流出6.951万港元。药明巨诺-B股票所在的生物技术行业中,整体跌幅为0.38%。其相关个股中,同源康医药-B、中国抗体-B、科笛-B涨幅较大,振幅较大的相关个股有圣诺医药-B、方达控股、晶泰科技,振幅分别为9.89%、8.96%、8.37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822102648971998f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822102648971998f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1574","02126"],"gpt_icon":0},{"id":"2460021155","title":"药明巨诺-B08月20日主力资金流出15万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2460021155","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460021155?lang=zh_cn&edition=full","pubTime":"2024-08-20 16:15","pubTimestamp":1724141723,"startTime":"0","endTime":"0","summary":"08月20日, 药明巨诺-B股价涨2.11%,报收1.45元,成交金额34万元,换手率0.06%,振幅3.52%,量比1.17。药明巨诺-B今日主力资金净流出15万元,连续3日净流出,上一交易日主力净流出14万元,今日环比增加7.14%。该股近5个交易日下跌2.03%,主力资金累计净流出62万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出126万元,其中净流出天数为6日。该股主力净额占比0.02%,港股市场排名2527/2638。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408201615419f3d0a3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408201615419f3d0a3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","02126","BK1161"],"gpt_icon":0},{"id":"2459149278","title":"药明巨诺-B(02126.HK)拟8月28日举行董事会会议批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2459149278","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459149278?lang=zh_cn&edition=full","pubTime":"2024-08-14 16:47","pubTimestamp":1723625238,"startTime":"0","endTime":"0","summary":"格隆汇8月14日丨药明巨诺-B(02126.HK)宣布,公司谨订于2024年8月28日(星期三)举行董事会会议,藉以(其中包括)(i)考虑及批准集团截至2024年6月30日止六个月的未经审核中期业绩及其发布;及(ii)处理任何其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814164718af975dc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814164718af975dc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02126","BK1583","BK1161"],"gpt_icon":0},{"id":"2458304764","title":"药明巨诺-B盘中异动 早盘急速上涨5.40%报1.581港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458304764","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458304764?lang=zh_cn&edition=full","pubTime":"2024-08-09 09:37","pubTimestamp":1723167441,"startTime":"0","endTime":"0","summary":"2024年08月09日早盘09时37分,药明巨诺-B股票出现波动,股价大幅上涨5.40%。截至发稿,该股报1.581港元/股,成交量5000股,换手率0.00%,振幅0.00%。药明巨诺-B股票所在的生物技术行业中,整体涨幅为0.29%。药明巨诺-B公司简介:药明巨诺(开曼)有限公司是一家主要从事临床及临床前阶段细胞治疗的中国公司。该公司致力于为中国市场开发细胞治疗手段,为中国癌症患者带来新兴治疗方式。该公司主要于中国市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809093722af96b40c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809093722af96b40c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02126","BK1574","BK1161"],"gpt_icon":0},{"id":"2457348898","title":"药明巨诺-B盘中异动 早盘股价大涨6.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457348898","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457348898?lang=zh_cn&edition=full","pubTime":"2024-08-07 09:53","pubTimestamp":1722995586,"startTime":"0","endTime":"0","summary":"2024年08月07日早盘09时53分,药明巨诺-B股票出现波动,股价大幅上涨6.03%。截至发稿,该股报1.601港元/股,成交量8.05万股,换手率0.02%,振幅4.64%。药明巨诺-B股票所在的生物技术行业中,整体跌幅为0.33%。药明巨诺-B公司简介:药明巨诺(开曼)有限公司是一家主要从事临床及临床前阶段细胞治疗的中国公司。该公司致力于为中国市场开发细胞治疗手段,为中国癌症患者带来新兴治疗方式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080709530696824907&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080709530696824907&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02126","BK1161","BK1574"],"gpt_icon":0},{"id":"2457832602","title":"药明巨诺-B(02126)股价上升5.298%,现价港币$1.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2457832602","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457832602?lang=zh_cn&edition=full","pubTime":"2024-08-07 09:53","pubTimestamp":1722995580,"startTime":"0","endTime":"0","summary":"[上升股]药明巨诺-B(02126) 股价在上午09:53比前收市价上升5.298%,现股价为港币$1.59。至目前为止,今日最高价为$1.59,而最低价为$1.53。总成交量为4.45万股,总成交金额为港币$6.95万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2408071082/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1583","02126","BK1161"],"gpt_icon":0},{"id":"2457981957","title":"药明巨诺-B(02126)下跌8.93%,报1.53元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2457981957","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457981957?lang=zh_cn&edition=full","pubTime":"2024-08-05 10:45","pubTimestamp":1722825910,"startTime":"0","endTime":"0","summary":"8月5日,药明巨诺-B(02126)盘中下跌8.93%,截至10:45,报1.53元/股,成交100.15万元。药明巨诺是一家专注于开发、生产和商业化细胞免疫治疗产品的创新型生物科技公司,目标是成为细胞免疫治疗领域的领导者。公司自2016年成立以来,已建立了涵盖血液肿瘤、实体肿瘤和自身免疫性疾病的细胞免疫治疗产品管线,并致力于用创新的、高品质的产品帮助全球患者得到治愈。截至2023年年报,药明巨诺-B营业总收入1.74亿元、净利润-7.68亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/05104542038523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1574","02126","BK1161"],"gpt_icon":0},{"id":"2457760420","title":"药明巨诺-B盘中异动 早盘股价大跌5.30%报1.591港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457760420","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457760420?lang=zh_cn&edition=full","pubTime":"2024-08-05 10:19","pubTimestamp":1722824341,"startTime":"0","endTime":"0","summary":"2024年08月05日早盘10时19分,药明巨诺-B股票出现异动,股价急速下挫5.30%。截至发稿,该股报1.591港元/股,成交量15.4万股,换手率0.04%,振幅7.14%。药明巨诺-B股票所在的生物技术行业中,整体涨幅为0.82%。药明巨诺-B公司简介:药明巨诺(开曼)有限公司是一家主要从事临床及临床前阶段细胞治疗的中国公司。该公司致力于为中国市场开发细胞治疗手段,为中国癌症患者带来新兴治疗方式。该公司主要于中国市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805101901941fde1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805101901941fde1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02126","BK1574","BK1161"],"gpt_icon":0},{"id":"2456478662","title":"药明巨诺-B盘中异动 临近收盘大幅跳水7.34%报1.640港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456478662","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456478662?lang=zh_cn&edition=full","pubTime":"2024-08-02 15:54","pubTimestamp":1722585276,"startTime":"0","endTime":"0","summary":"2024年08月02日临近收盘15时54分,药明巨诺-B股票出现异动,股价急速下挫7.34%。截至发稿,该股报1.640港元/股,成交量24.8万股,换手率0.06%,振幅9.04%。药明巨诺-B股票所在的生物技术行业中,整体跌幅为0.54%。药明巨诺-B公司简介:药明巨诺(开曼)有限公司是一家主要从事临床及临床前阶段细胞治疗的中国公司。接任李怡平的是刘敏,其获任药明巨诺行政总裁及执行董事。同日,药明巨诺向界面新闻表示,李怡平本人暂未透露此后的职业去向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802155438aefce3d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802155438aefce3d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","02126","BK1161"],"gpt_icon":0},{"id":"2456478694","title":"药明巨诺-B(02126)股价下跌5.65%,现价港币$1.67","url":"https://stock-news.laohu8.com/highlight/detail?id=2456478694","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456478694?lang=zh_cn&edition=full","pubTime":"2024-08-02 15:54","pubTimestamp":1722585240,"startTime":"0","endTime":"0","summary":"[下跌股]药明巨诺-B(02126) 股价在下午03:54比前收市价下跌5.65%,现股价为港币$1.67。至目前为止,今日最高价为$1.8,而最低价为$1.67。总成交量为8.65万股,总成交金额为港币$14.976万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2408023790/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","BK1161","BK1574","02126"],"gpt_icon":0},{"id":"2456096331","title":"信达前CCO刘敏履新药明巨诺CEO,能否卖好“天价疗法”?","url":"https://stock-news.laohu8.com/highlight/detail?id=2456096331","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456096331?lang=zh_cn&edition=full","pubTime":"2024-08-01 18:11","pubTimestamp":1722507076,"startTime":"0","endTime":"0","summary":"接任李怡平的是刘敏,其获任药明巨诺行政总裁及执行董事。公告称,李怡平确认其不向公司提出任何申索,与董事会也无意见分歧。前述变动均在7月31日生效。同日,药明巨诺向界面新闻表示,李怡平本人暂未透露此后的职业去向。当时,信达生物向界面新闻回应称,刘敏辞职系因其“个人原因”。2023年,药明巨诺营收1.74亿元,同比增长19.3%,全部来自倍诺达销售收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408011814179f054032&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408011814179f054032&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02126","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2455360071","title":"药明巨诺CEO李怡平离职,称目前无创业打算,前信达生物CCO刘敏接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2455360071","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455360071?lang=zh_cn&edition=full","pubTime":"2024-07-31 21:04","pubTimestamp":1722431057,"startTime":"0","endTime":"0","summary":"7月31日,药明巨诺-B宣布换帅,信达生物前首席商务官刘敏加盟,接替李怡平担任公司执行董事兼行政总裁职务。对于突然的离职以及下一阶段是否有创业打算,李怡平表示,自己已经到了法定退休年纪,目前没有创业打算。药明巨诺发布的公告显示,刘敏已获委任为本公司行政总裁及执行董事,自2024年7月31日起生效。在加入药明巨诺之前,刘敏最为业内熟知的身份是信达生物前首席商务官。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407312104319f022129&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407312104319f022129&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02126","LU1969619763.USD","LU2328871848.SGD","01801","BK1583","BK1589","BK1161"],"gpt_icon":0},{"id":"2455739183","title":"药明巨诺换帅:刘敏接任首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2455739183","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455739183?lang=zh_cn&edition=full","pubTime":"2024-07-31 18:33","pubTimestamp":1722421980,"startTime":"0","endTime":"0","summary":"南方财经7月31日电,药明巨诺宣布任命刘敏为公司的首席执行官,自今日起生效。同时,刘敏还将担任药明巨诺董事会的执行董事。据悉,在加入药明巨诺前,刘敏曾担任信达生物制药首席商务官、罗氏(中国)副总裁。根据公告,李怡平医生因希望为家人和其他个人兴趣投入更多时间,已辞任药明巨诺首席执行官,过渡期间他将继续担任董事会主席,为其继任者提供支持,确保顺利过渡。(21世纪经济报道)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024073118334695712ec5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024073118334695712ec5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02126","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2455790275","title":"【药明巨诺-B(02126.HK):刘敏已获委任为行政总裁及执行董事】智通财经APP讯,药明巨诺-B(02126.HK)发布公告,刘敏已获委任为公司行政总裁及执行董事,自2024年7月31日起生效。","url":"https://stock-news.laohu8.com/highlight/detail?id=2455790275","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455790275?lang=zh_cn&edition=full","pubTime":"2024-07-31 17:57","pubTimestamp":1722419855,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02126","BK1161","BK1574"],"gpt_icon":0},{"id":"2455027429","title":"药明巨诺-B(02126):刘敏已获委任为行政总裁及执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2455027429","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455027429?lang=zh_cn&edition=full","pubTime":"2024-07-31 17:57","pubTimestamp":1722419855,"startTime":"0","endTime":"0","summary":"智通财经APP讯,药明巨诺-B 发布公告,刘敏已获委任为公司行政总裁及执行董事,自2024年7月31日起生效。董事会已调任李医生为非执行董事,自2024年7月31 日起生效,过渡期间彼将继续担任董事会主席,为其继任者提供支持,确保顺利过渡。董事会亦宣布任命公司行政总裁兼执行董事刘先生接替李医生担任上市规则第3.05条规定的公司授权代表,自2024年7月31日起生效。紧随上述变更后,授权代表为刘先生及公司公司秘书吴嘉雯女士。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1158087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","02126","BK1161"],"gpt_icon":0},{"id":"2455900645","title":"药明巨诺(02126.HK)委任首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2455900645","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455900645?lang=zh_cn&edition=full","pubTime":"2024-07-31 17:56","pubTimestamp":1722419760,"startTime":"0","endTime":"0","summary":"药明巨诺(02126.HK) 宣布,执行董事兼首席执行官李怡平(Yiping James Li)因希望为家人和其他个人兴趣投入更多时间,已辞任公司首席执行官职务,并已调任为非执行董事,自今日(31日)起生效。董事会宣布,刘敏已获委任为公司首席执行官及执行董事,同日起生效。在过渡期间,李怡平将继续担任董事会主席,为继任者提供支持。(gc/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210524130514376_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210524130514376_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1367884/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02126","BK1583","BK1161"],"gpt_icon":0},{"id":"2455684824","title":"药明巨诺-B盘中异动 大幅跳水5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2455684824","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455684824?lang=zh_cn&edition=full","pubTime":"2024-07-29 14:49","pubTimestamp":1722235754,"startTime":"0","endTime":"0","summary":"2024年07月29日下午盘14时49分,药明巨诺-B股票出现波动,股价快速跳水5.00%。截至发稿,该股报1.710港元/股,成交量7.7676万股,换手率0.02%,振幅6.67%。药明巨诺-B股票所在的生物技术行业中,整体跌幅为0.42%。药明巨诺-B公司简介:药明巨诺(开曼)有限公司是一家主要从事临床及临床前阶段细胞治疗的中国公司。该公司致力于为中国市场开发细胞治疗手段,为中国癌症患者带来新兴治疗方式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240729144914aefbe5c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240729144914aefbe5c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02126","BK1583"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.089},{"period":"1month","weight":-0.2443},{"period":"3month","weight":-0.4115},{"period":"6month","weight":-0.335},{"period":"1year","weight":-0.4167},{"period":"ytd","weight":-0.4115}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明巨诺(开曼)有限公司是一家主要从事临床及临床前阶段细胞治疗的中国公司。该公司致力于为中国市场开发细胞治疗手段,为中国癌症患者带来新兴治疗方式。通过其子公司,其建立了一个专注为血液癌症及实体瘤开发、制造和商业化突破性细胞免疫疗法的一体化平台。其主打候选产品relmacabtagene autoleucel(relma-cel)是针对复发或难治(r/r)B细胞淋巴瘤的自体抗CD19 CAR-T疗法。该公司主要于中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01079},{"month":2,"riseRate":0.75,"avgChangeRate":0.067143},{"month":3,"riseRate":0,"avgChangeRate":-0.17939},{"month":4,"riseRate":0.25,"avgChangeRate":-0.041215},{"month":5,"riseRate":0.5,"avgChangeRate":0.022518},{"month":6,"riseRate":0.25,"avgChangeRate":-0.080401},{"month":7,"riseRate":0.25,"avgChangeRate":-0.08945},{"month":8,"riseRate":0,"avgChangeRate":-0.179976},{"month":9,"riseRate":0,"avgChangeRate":-0.221444},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.041718},{"month":11,"riseRate":0.666667,"avgChangeRate":0.315863},{"month":12,"riseRate":0.75,"avgChangeRate":-0.039996}],"exchange":"SEHK","name":"药明巨诺-B","nameEN":"JW THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明巨诺-B(02126)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明巨诺-B(02126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明巨诺-B,02126,药明巨诺-B股票,药明巨诺-B股票老虎,药明巨诺-B股票老虎国际,药明巨诺-B行情,药明巨诺-B股票行情,药明巨诺-B股价,药明巨诺-B股市,药明巨诺-B股票价格,药明巨诺-B股票交易,药明巨诺-B股票购买,药明巨诺-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明巨诺-B(02126)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明巨诺-B(02126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}